Literature DB >> 22980691

Management of well-differentiated thyroid cancer.

Selena Liao1, Maisie Shindo.   

Abstract

This review provides an overview of current guideline recommendations for the clinical evaluation and surgical management of well-differentiated thyroid cancer, and further examines the evidence for controversial topics such as the minimum degree of primary resection, the role of elective central neck dissection, and the extent of lateral neck dissection. Well-differentiated thyroid cancer comprises the majority of thyroid cancers, about 90%, and includes both papillary and follicular carcinomas. Despite convergence of the medical community in establishing treatment guidelines under the American Thyroid Association, there still remain many areas of disagreement.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22980691     DOI: 10.1016/j.otc.2012.06.015

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  5 in total

1.  Papillary thyroid cancer in a gravid woman.

Authors:  Darrin V Bann; Neerav Goyal; David Goldenberg
Journal:  Ear Nose Throat J       Date:  2014-07       Impact factor: 1.697

2.  Multifocal metastases to choroid plexus from papillary thyroid carcinoma: illustrative case.

Authors:  Isidora R Beach; Adam M Olszewski; Alissa A Thomas; John C DeWitt; Brandon D Liebelt
Journal:  J Neurosurg Case Lessons       Date:  2021-09-13

Review 3.  Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?

Authors:  Paul J Davis; Aleck Hercbergs; Mary K Luidens; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2014-10-08       Impact factor: 3.869

Review 4.  Standards and Definitions in Neck Dissections of Differentiated Thyroid Cancer.

Authors:  Mehmet Uludağ; Mert Tanal; Adnan İşgör
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2018-10-01

5.  Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.

Authors:  Jui-Yu Chen; Jane-Jen Wang; Hsin-Chen Lee; Chin-Wen Chi; Chen-Hsen Lee; Yi-Chiung Hsu
Journal:  J Chin Med Assoc       Date:  2020-10       Impact factor: 3.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.